XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more
XTL Biopharmaceuticals Ltd - Asset Resilience Ratio
XTL Biopharmaceuticals Ltd (XTLB) has an Asset Resilience Ratio of 9.03% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how XTL Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down XTL Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA772.00K | 9.03% |
| Total Liquid Assets | ILA772.00K | 9.03% |
Asset Resilience Insights
- Limited Liquidity: XTL Biopharmaceuticals Ltd maintains only 9.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
XTL Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare XTL Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for XTL Biopharmaceuticals Ltd (2013–2024)
The table below shows the annual Asset Resilience Ratio data for XTL Biopharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.03% | ILA772.00K | ILA8.55 Million | -15.91pp |
| 2023-12-31 | 24.94% | ILA605.00K | ILA2.43 Million | -13.93pp |
| 2022-12-31 | 38.87% | ILA1.63 Million | ILA4.19 Million | -8.85pp |
| 2021-12-31 | 47.72% | ILA3.16 Million | ILA6.62 Million | +10.64pp |
| 2020-12-31 | 37.08% | ILA2.41 Million | ILA6.50 Million | +5.56pp |
| 2019-12-31 | 31.52% | ILA2.27 Million | ILA7.21 Million | +7.96pp |
| 2018-12-31 | 23.56% | ILA2.02 Million | ILA8.57 Million | -14.51pp |
| 2017-12-31 | 38.07% | ILA2.51 Million | ILA6.59 Million | +24.34pp |
| 2016-12-31 | 13.72% | ILA414.00K | ILA3.02 Million | +9.01pp |
| 2015-12-31 | 4.72% | ILA251.00K | ILA5.32 Million | -11.23pp |
| 2013-12-31 | 15.95% | ILA1.28 Million | ILA8.02 Million | -- |